Page 22 - 82_03
P. 22
Biological relevance of a mysterious hydroxyl group Biochimie 2001; 83: 623-34.
concentrations of markers of inflammation and 48. Mukerjee S, Nasoff M, Glassy M. Characterization of
endothelial dysfunction. Am J Clin Nutr 2004; 80: human IgG1 monoclonal antibody against
1029–35 gangliosides expressed on tumor cells. Hybridoma
1998; 17: 133-42.
35. Hanganutziu M. Hémagglutinines hétérogénétiques
après injection de sérum de cheval. CR Séances Soc 49. Huang ZH, Shi L, Ma JW, Sun ZY, et al. A totally
Biol 1924; 91:1457-59. synthetic, self-assembling, adjuvant-free MUC1
glycopeptide vaccine for cancer therapy. J Am Chem
36. Merrick JM, Zadarlik K, Milgrom F. Characterization Soc 2012; 134: 8730-33.
of the Hanganutziu-Deicher (serum-sickness) antigen
as gangliosides containing N-glycolylneuraminic acid. 50. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK.
Int Arch Allergy Appl Immunol 1978; 57: 477-80. Mucins in pancreatic cancer and its
microenvironment. Nat Rev Gastroenterol Hepatol
37. Varki A. Uniquely human evolution of sialic acid 2013; 10: 607-20.
genetics and biology. Proc Nat Acad Sci 2010; 107:
8939-46. 51. a) Marquina G, Waki H, Fernández LE, Kon K, et al.
Gangliosides expressed in human breast cáncer.
38. Samraj AN, Läubli H, Varki N, Varki A. Involvement Cancer Res 1996; 56: 5165-71. b) van Cruijsen
of a non-human sialic acid in human cancer. Front H, Gallegos Ruiz M, van der Valk P, de Gruijl
Oncol 2014; 4: 33. TD, Giaccone G. Tissue micro array analysis of
ganglioside N-glycolyl GM3 expression and signal
39. Padler-Karavani V, Yu H, Cao H, Chokhawala H, et transducer and activator of transcription (STAT)-3
al. Diversity in Specificity, Abundance and activation in relation to dendritic cell infiltration and
Composition of Anti-Neu5Gc Antibodies in Normal microvessel density in non-small cell lung cáncer.
Humans: Potential Implications for Disease”. BMC Cancer 2009; 9: 180.
Glycobiology 2008; 18: 818-30.
52. Carr A, Rodríguez E, Arango MC, Camacho R, Osorio
40. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, M, Gabri M, et al. Immunotherapy of advanced breast
et al. Novel mechanism for the generation of human cancer with a heterophilic ganglioside (NeuGcGM3)
xeno-auto-antibodies against the nonhuman sialic acid cancer vaccine. J Clin Oncol 2003; 21: 1015-2110.
N-glycolylneuraminic acid. J Exp Med 2010; 207:
1637-46. 53. a) Carr A, Mullet A, Mazorra Z, Vázquez AM, et al. A
mouse IgG1 monoclonal antibody specific for N-
41. Bergfeld AK, Pearce OMT, Diaz SL, Pham T, Varki Glycolyl GM3 Ganglioside recognized breast and
A. Metabolism of Vertebrate Amino Sugars with N- melanoma tumors. Hybridoma 2000; 19: 241-47. b)
Glycolyl Groups. Elucidating the intracelular fate of Carr A, Mesa C, Arango MC, Vázquez AM, et al. In
the non-human sialic acid N-glycolylneuraminic acid. Vivo and In Vitro Anti-Tumor Effect of 14F7
J Biol Chem 2012; 287: 28865-81. Monoclonal Antibody. Hybridoma and Hybridomics,
2002; 21: 463-68.
42. Scheinthal BM, Bettelheim FA. Multiple forms of
sialic acids. Carbohydr Res 1988; 6, 257-65. 54. Lu Q, Padler-Karavani V, Yu H, Chen X, Wu SL, et
al. LC-MS analysis of polyclonal human anti-Neu5Gc
43. Eylar EH, Madoff MA, Brody OV, Oncley JL. The Xeno-autoantibodies IgG subclass and partial
contribution of sialic acid to the surface charge of sequence using multi-step IVIG affinity purification
erythrocyte. J Biol Chem 1962; 237: 1992-2000. and multi-enzymatic digestion. Anal Chem 2012; 84:
2761-68.
44. Varki A, Kannagi R, Toole BP. Glycosylation changes
in cancer. In: Varki A, Cummings RD, Esko JD, 55. Roque-Navarro L, Chakrabandhu K, de Leon J,
Freeze HH, Stanley P, Bertozzi CR, et al. Eds. Rodríguez S, et al. Anti-ganglioside antibody-induced
Essentials of Glycobiology. NY: Cold Spring Harbor tumor cell death by loss of membrane integrity. Mol
Laboratory Press 2009: pp. 617-32. Cancer Ther 2008; 7: 2033-41.
45. Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of 56. a) Fernández-Marrero Y, Hernández T, Roque-Navarro
tumor-associated gangliosides in cancer progression. L, Talavera A, et al. Switching on cytotoxicity by a
Biochimie 2003; 285: 455-63. single mutation at the heavy chain variable region of
an anti-ganglioside antibody. Mol. Immunol. 2011;
46. (a) Buskas T, Thompson P, Boons J-G. 48: 1059-67. b) Fernández-Marrero Y, Roque-Navarro
Immunotherapy for cancer: synthetic carbohydrate- L, Hernández T, Dorvignit D, et al. A cytotoxic
based vaccines. Chem Commun 2009; 5335-49. (b) humanized anti-ganglioside antibody produced in a
Zhu J, Warren JD, Danishefsky SJ. Synthetic murine cell line defective of N-glycolylated-
carbohydrate-based anticancer vaccines: the Memorial glycoconjugates. Immunobiology 2011; 216: 1239-47.
Sloan-Kettering experience. Expert Rev Vaccines
2009; 8:1399-1413; (c) Yin Z, Huang X. Recent 57. Rojas G, Pupo A, Gómez S, Krengel U, Moreno E.
Development in Carbohydrate Based Anticancer Engineering the Binding Site of an Antibody against
Vaccines. J Carbohydr Chem 2012; 31:143-86; (d) N-Glycolyl GM3: From Functional Mapping to Novel
Fernández-Tejada A, Danishefsky SJ. Carbohydr
Chem 2014; 40: 506-32. 281
47. Malykh YN, Schauer R, Shaw L. N-
Glycolylneuraminic acid in human tumours.
@Real Academia Nacional de Farmacia. Spain
